Bruker 10-Q Details $309.4M Nine-Month Goodwill Impairment and $0.81 Q3 Loss
BRKR sits 79% above its 52-week low of $32.365.
Summary
Bruker's Q3 10-Q confirms the $874.0M revenue and $0.56 non-GAAP EPS already reported, and details a $111.8M quarterly net loss after $174.5M of goodwill impairment, $309.4M of impairments for the nine months, and cash down to $119.7M.
Key Events · Earnings and Guidance · BRKR
-
Q3 Loss Driven by Goodwill Write-Down
Net loss attributable to Bruker was $111.8M, or $0.81 per share, versus $59.6M a year earlier, after a $174.5M goodwill impairment on the BSB&CA reporting unit.
-
Nine-Month Impairments Reach $309.4M
Goodwill impairment totaled $309.4M for the nine months, including $211.0M on BSB&CA and $98.4M on CST; both reporting units now carry no remaining goodwill.
-
Margins Expand on Cost Cuts
Gross margin rose to 49.1% from 44.1% and non-GAAP operating margin to 16.3% from 12.3%, helped by lower restructuring costs and cost savings initiatives.
-
Cash Falls on Debt Repayment
Cash and equivalents dropped to $119.7M from $298.8M at December 31, 2025, after $186.3M of long-term debt repayment and $55.8M of preferred and common dividends; $783.9M remains available on the $900M revolver.
Analysis · BRKR · Industrial Applications And Services
The headline numbers were already out on November 4, but the full 10-Q fills in what the press release only summarized: a $111.8M net loss attributable to Bruker in Q3 ($0.81 per share) and $149.4M for the nine months, driven by $309.4M of goodwill impairment taken in 2026 — $98.4M on the CST unit and $211.0M on BSB&CA, which now carries no goodwill at all. Those are non-cash charges, and the underlying business is holding up: gross margin rose to 49.1% from 44.1% and non-GAAP operating margin to 16.3% from 12.3% on cost cuts. The real balance-sheet story is cash, which fell to $119.7M from $298.8M at year-end after $186.3M of debt repayment and $55.8M of dividends, leaving the $900M revolver ($783.9M available) as the liquidity backstop. Also new here: the September 15 amendments to all four note purchase agreements, which let Bruker use a more favorable trailing exchange rate in the leverage covenant — a modest but real sign the strong dollar was pressing on covenant headroom.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRKR was trading at $58.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8.8B. The 52-week trading range was $32.37 to $68.98. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.